TheFly.com
PSTV
Plus Therapeutics
$
()
Plus Therapeutics receives $3M award recommendation from U.S. DOD
Plus Therapeutics appoints Andrew Brenner, Barbara Blouw to management team
Plus Therapeutics announces validation, implementation of CSF-01 diagnostic
Plus Therapeutics completes dosing in Cohort 5 of ReSPECT-LM Phase 1 trial
Plus Therapeutics reports FY23 EPS ($4.24) vs ($11.58) last year
Plus Therapeutics expects cash to fund operations to 2H25
Plus Therapeutics partners with K2bio to develop novel tests for CSF analyses
Plus Therapeutics files to sell common stock, warrants, no amount given
Plus Therapeutics reports interim ReSPECT-GBM Phase 2 trial data
Plus Therapeutics files to sell 1.3M shares of common stock for holders
Plus Therapeutics granted Orphan Drug Designation for rhenium obisbemeda
Plus Therapeutics gets orphan designation for breast cancer treatment
Copyright ©1998-2024 Thefly.com LLC
